

Regular Review

Strategies for prevention of osteoporosis and hip fracture

M R Law, N J Wald, T W Meade

In England in 1985, 37 600 people aged 65 years and over fractured a hip.<sup>1</sup> On average 3170 acute hospital beds a day were committed to people over 65 with hip fracture—nearly a quarter of all orthopaedic beds. Table I shows the age and sex distribution of patients with hip fracture. In all, 82% of those aged 65 and over were women, of whom 83% were aged 75 and over. On the basis of the present incidence (table II) almost one woman in four living to the age of 90 in England can expect to have a hip fracture. Age specific rates

TABLE I—Number of hospital discharges and deaths (rate per 10 000 population) for fractured neck of femur, by age and sex in England, 1985 (from Hospital Inpatient Enquiry data<sup>1</sup>)

Age (years)	No (rate/10 000) in men	No (rate/10 000) in women
0-44	1330 (0.9)	650 (0.5)
45-64	1370 (2.7)	2240 (4.3)
65-74	1890 (10.4)	5330 (23.0)
75-84	3010 (34.1)	14 310 (90.1)
≥85	1840 (136.2)	11 260 (252.5)
Total No ≥65	6740	30 900

TABLE II—Cumulative probability of person aged 45 sustaining hip fracture by age (calculated on life table basis from data in table I)

Age (years)	Probability in men (%)	Probability in women (%)
65	0.5	1
75	2	3
85	5	11
90	11	22

doubled over the 25 years to about 1980,<sup>2,3</sup> and while rates seem not to have further increased over the past decade,<sup>3</sup> the absolute number of fractures occurring each year is still expected to increase for the next few decades as the proportion of elderly people in the population rises. With serious complications such as failure to regain mobility, pressure sores, pneumonia, and the precipitation of confusional states and dementia, hip fracture is a major cause of morbidity and institutional care in elderly people. In this review we assess quantitatively the relative merits of different strategies for preventing the loss of bone mineral density (osteoporosis) that is the pathological basis for hip fracture.

Bone mineral density and fracture

The mineral density of bone is essentially the mass of calcium salts per unit volume. It is calculated directly from the ash weight of bone after incineration, but can be accurately estimated by techniques such as photon or x ray absorptiometry.<sup>4</sup> A direct linear association between bone mineral density and the minimum force needed to fracture the neck of the femur has been shown by experiments in which incremental mechanical forces were applied to the necks of human femurs mounted in blocks.<sup>4,6</sup> For a given bone density, however, there was about a twofold range of values among femurs for the minimum force needed for fracture, suggesting that the overall mineral density may be a relatively crude measure of the resistance to fracture of an individual neck of a femur.

Several longitudinal and cross sectional studies have examined changes in bone mineral density with age.<sup>7-17</sup> Bone density approaches its peak value by early adulthood, and remains stable for some years. In women, premenopausal bone loss from the femur and other long bones is normally slight, but rapid bone loss begins at the menopause. Thereafter bone loss continues throughout life, although the rate slows after several years. Peak bone density and subsequent rate of bone loss may not be closely associated; both are important determinants of individual bone density in old age. At any age bone density is on average lower in women than in men, but there is a wide range among individuals. Women on average lose between a third and a half of their peak bone mass over their lifetime, while men lose less. Differences in bone density are likely, at least in part, to account for the sex difference in incidence of hip fracture in elderly people and for the increasing incidence in both sexes with advancing age. Bone loss in older people is largely irreplaceable, though it may not be completely so. Strategies aimed at preventing low bone density in old age should be directed particularly at women and should begin at the time of the menopause because of the rapid and largely irreversible bone loss thereafter.

Preventive strategies

When the risk of a disease varies according to the magnitude of a continuously distributed variable (in this case bone density) two different preventive strategies can be adopted—screening, in which intervention is restricted to people with results beyond a specified cut off level, and the population approach, in which the aim is to shift the entire distribution of the variable in a favourable direction by intervention in everyone, without necessarily measuring the variable.

Screening is unlikely to be worth while if there is little difference between the average bone density of those who do and those who do not suffer fractures. The potential value of measurement of bone density in menopausal women as a screening test for future hip fracture is best assessed by estimating the separation between the distribution of bone density in elderly women who fracture their hip and that in elderly women who do not fracture their hip. This can be done either retrospectively, by measuring bone density in patients with hip fractures and in control subjects, or prospectively, by measuring bone density in a large population and recording hip fractures as they occur.

1 Screening by measuring bone mineral density

STUDIES OF BONE MINERAL DENSITY AND HIP FRACTURE

Table III summarises data from studies that have compared bone mineral density in women with hip

Wolfson Institute of Preventive Medicine, Medical College of St Bartholomew's Hospital, London EC1M 6BQ

M R Law, MRCP  
N J Wald, FRCP  
T W Meade, FRCP

Correspondence to: Dr Law.

BMJ 1991;303:453-9

fracture with that in age matched controls representing the normal population. These studies estimated the average difference in bone density at the time of the fracture. Units of measurement vary among the studies, and to permit a valid comparison we have expressed each case-control difference as a proportion of the standard deviation of the bone density of the controls in that study. (This assumes a linear relation between the different units of measurement, which may not be strictly true but is a reasonable approximation.)

Measurement of bone density of the contralateral femoral neck provides the most direct evidence (the left and right sides are normally highly correlated<sup>1</sup>). Immobility after a fracture, however, will cause bone loss from the femur and introduce bias if the measurement is not performed soon after the fracture. The five studies included in table III that measured bone density of the contralateral neck of the femur minimised this bias either by performing the measurement within 10 days of the fracture or by

mobilising the patients within a few days of the fracture. Three studies that did not meet these criteria were excluded.<sup>24 25 36</sup>

For the five studies included in table III that measured bone density directly at the neck of the femur the difference in bone density between patients with hip fracture and controls was only about half a standard deviation—too small for an effective screening test. The figure illustrates this by showing the Gaussian distributions of bone density in patients with hip fracture and controls, half a standard deviation apart. The area under the hip fracture curve to the left of a given cut off level, expressed as a proportion of the area under the whole curve, indicates the detection rate—that is, the proportion of women who have hip fracture with a bone mineral density less than or equal to the given cut off value. Similarly, the area under the control curve to the left of the same cut off level indicates the corresponding false positive rate—that is, the proportion of unaffected women with a bone mineral density value less than or equal to the given cut off value. For example, at a cut off of two standard deviations below the mean for the controls the detection rate would be 6% and the false positive rate 2%; at 1.6 standard deviations below the mean the rates would be 13% and 5% respectively. There is too much overlap between the two distributions for measurement of bone density to be a worthwhile screening test. In practice the discrimination would be even worse because with measurement at the menopause, 20-30 years before the fracture, the degree of overlap would be greater than that at the time of the fracture. The expected benefits of screening would be still further reduced because no treatment is likely to prevent all hip fractures.

The studies listed in table III that measured bone density at sites other than the neck of the femur confirm that bone density measurement is a poor screening test. The average difference between cases and controls was 0.3 standard deviations, and the correlation coefficient between bone density at the neck of the femur and at other sites is about 0.6<sup>18 19 25</sup>; the average difference divided by the correlation coefficient estimates the difference in bone density between cases and controls at the neck of the femur; in this case the estimate is half a standard deviation, the same as the direct result.


Prospective studies of bone density and hip fracture have not been conducted over a long enough period to determine the value of measurement of bone density at the menopause in predicting hip fractures some 20 or 30 years later. They have, however, shown that the risk of a hip fracture within a few years of measurement of bone density is similar to that estimated from the case-control studies. The variation in risk from the 10th to 90th centile values of bone density was only twofold to fourfold,<sup>37-42</sup> a weak gradient that can be shown to be equivalent to a separation of about half a standard deviation between the bone density distributions of those who will subsequently have a hip fracture and those who will not—the same estimate as was derived from the case-control studies. On the basis of all the epidemiological evidence, retrospective and prospective, there is at present no scientific case for screening.

This poor performance of measurement of bone density as a screening test does not imply that bone density is unimportant in the aetiology of hip fracture, it simply indicates that most elderly women have lost sufficient bone for the hip to fracture with the impact of an unprotected fall. Differences in bone density between individual women are not great enough to discriminate between who will and who will not later suffer a fracture; this will be determined by chance, by conditions that increase the risk of falling or cause loss of the normal protective reflexes, and by illness

TABLE III—Bone density measurements in women with hip fracture and age matched controls in various studies

Study	Site	Measurement technique	No of cases/controls	Difference between cases and controls in bone density* (standard deviations)
<i>Neck of femur†</i>				
Bohr and Schaad <sup>18</sup>	Contralateral neck of femur	Dual photon absorptiometry	46/38	-0.4
Eriksson and Widhe <sup>9</sup>			62/39	-0.5
Riggs, Melton <i>et al</i> <sup>15, 16, 20</sup>			49/166	-0.4
Norimatsu <i>et al</i> <sup>17</sup>			12/31	-0.75
Chevalley <i>et al</i> <sup>21</sup>			57/82	-0.6
Weighted average				-0.5
<i>Other sites†</i>				
Bohr and Schaad <sup>18</sup>	Lumbar spine	Dual photon absorptiometry	46/38	-0.1
Chevalley <i>et al</i> <sup>21</sup>			57/82	-0.1
Krolner and Pors Nielsen <sup>22</sup>			36/38	+0.4
Cornell <i>et al</i> <sup>23</sup>			54/269	-0.3
Riggs <i>et al</i> <sup>16</sup>			22/95	+0.2
Meltzer <i>et al</i> <sup>24</sup>	16/92	-0.3		
Mazess <i>et al</i> <sup>25</sup>	37/278	-0.7		
Härmä <i>et al</i> <sup>26</sup>	Lumbar spine	Computed tomography	30/49	-0.8
Firooznia <i>et al</i> <sup>27</sup>			83/207	-0.3†
Wootton <i>et al</i> <sup>28</sup>	Forearm	Single photon absorptiometry	30/23	-0.2
Riggs <i>et al</i> <sup>16</sup>			26/95	+0.1
Jensen <i>et al</i> <sup>29</sup>			10/160	-0.8
Meltzer <i>et al</i> <sup>24</sup>	16/92	-0.1		
Mazess <i>et al</i> <sup>25</sup>	37/278	-0.5		
Elsasser <i>et al</i> <sup>30</sup>	Radius	Computed tomography	32/28	-0.4
Härmä <i>et al</i> <sup>26</sup>			29/49	-0.6
Lips <i>et al</i> <sup>31</sup>	Metacarpals	Radiographic	67/54	-0.4
Aitken <sup>32</sup>			195/317	+0.2†
Cook <i>et al</i> <sup>33</sup>			314/370	-0.5†
Horsman <i>et al</i> <sup>34</sup>	58/58	-0.4		
Horsman <i>et al</i> <sup>34</sup>	Femoral shaft	Radiographic	58/58	-0.7
Chevalley <i>et al</i> <sup>21</sup>	Femoral shaft	Dual photon absorptiometry	57/82	-0.2
Bohr and Schaad <sup>18</sup>			46/38	-0.6
Hassager and Christiansen <sup>35</sup>	Total body	Dual photon absorptiometry	27/26	-0.9
Weighted average				-0.3

\*A negative value indicates lower bone density in cases. †Difference estimated from data displayed graphically.



Distribution of bone mineral density in women with hip fracture and age matched controls. Implied vertical axis is proportion of cases and controls within a marginal unit of bone density. Expected screening performance of measurement is shown by three examples

TABLE IV—Cumulative percentages of the Singh index grades in case-control studies of patients with hip fracture by age

Study	Singh grade*	50-64 years		65-74 years		75-84 years		≥85 years	
		Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
Cooper <i>et al</i> <sup>11</sup>	1-2	(n=52) 13%	(n=82) 1%	(n=93) 12%	(n=61) 2%	(n=180) 24%	(n=69) 9%	(n=131) 33%	(n=40) 15%
	1-3	29%	4%	43%	13%	53%	23%	64%	43%
	1-4	73%	20%	75%	39%	81%	62%	94%	85%
Poggrund <i>et al</i> <sup>14</sup>	1-2	(n=67) 16%	(n=207) 0	(n=137) 22%	(n=181) 0	(n=170) 25%	(n=737) 1%		
	1-3	40%	0	39%	0	55%	5%		
	1-4	60%	2%	66%	1%	77%	13%		
Dequeker <i>et al</i> <sup>15</sup>	1-2			(n=13) 46%	(n=24) 0%				
	1-3			100%	13%				
	1-4			100%	38%				
Horsman <i>et al</i> <sup>16</sup>	1-2			(n=58)† 26%	(n=58) 0				
	1-3			57%	7%				
	1-4			88%	29%				
Lips <i>et al</i> <sup>17</sup>	1-2					(n=118)‡ 1%	(n=74) 0		
	1-3					18%	1%		
	1-4					64%	20%		

\*Grade 6 = normal trabecular pattern in neck of femur, grade 1 = extreme trabecular loss.

†Mean age 70, range 47-92 years.

‡Mean (SD) age 76 (11) years.

TABLE V—Studies of relative risk of hip fracture in women who had or had not ever received hormone replacement therapy

Study centre	Age range (mean) (years)	No of cases who had/had not received hormone replacement therapy	No of controls who had/had not received hormone replacement therapy	Relative risk (95% confidence interval)
<i>Case-control studies</i>				
Seattle <sup>18</sup>	50-74	52/108	293/274	0.4 (0.3 to 0.6)*†
Oregon <sup>19</sup>	52-80 (70)	49/119	121/215	0.7 (0.5 to 1.1)
Los Angeles <sup>21</sup>	<80 (72)	35/46	85/80	0.7 (0.4 to 1.2)†
Connecticut <sup>22</sup>	45-74 (67)	14/80	213/579	0.5 (0.2 to 0.9)*
Southampton (UK) <sup>23</sup>	50-99 (78)	6/234	23/457	0.5 (0.2 to 1.3)
New Haven <sup>24</sup>	<80 (70)	3/68	12/59	0.2 (0.1 to 0.7)†
<i>Prospective studies</i>				
Los Angeles <sup>25</sup>	(76)‡	163/166		1.0 (0.8 to 1.3)
Framingham <sup>26</sup>	64-96 (75)	28/135		0.6 (0.4 to 0.9)*

\*Adjusted for the effect of other risk factors.

†Calculated by us from published data.

‡Median age.

and immobility causing bone loss shortly before the fracture.

#### SINGH INDEX AND HIP FRACTURE

Table IV lists studies that have measured the Singh index (a radiological estimate of the extent of loss of the bony trabeculae in the femoral neck graded from 1 (gross trabecular loss) to 6 (normal trabecular pattern)) in patients with hip fracture and age matched controls. They suggest that at the time of fracture the Singh index can identify a small proportion of the general population in which most of the hip fractures cluster. For example, many of the cases but few of the controls had Singh grades of 1-3. The separation between cases and controls was weaker over the age of 75, although more data are needed to be certain.

The Singh index correlates poorly with bone mineral density,<sup>5,18</sup> and the reason that it can predict hip fracture risk (at least up to the age of 75) whereas bone mineral density measurements cannot, could be that the contribution of the trabecular elements to the strength of the proximal femur is large (about 70%) compared with their relatively small contribution to overall bone density (cortical and trabecular).<sup>46</sup> Trabecular bone density, measured by quantitative computed tomography, correlated highly with the compressive strength of the proximal femur.<sup>46</sup>

People at high risk of hip fracture may have extensive loss of trabecular bone (and a low Singh index) but not necessarily have low overall bone mineral density in the neck of the femur. Screening by using the Singh index (or quantitative computed tomography) might therefore be feasible in theory, but for several reasons it would not perform well in practice. The Singh index in old age cannot be predicted at the menopause;

the reproducibility of Singh index grading between observers is poor<sup>17</sup> (the case-control studies each used only one or two observers); the radiation exposure is significant; and discrimination seems poor over the age of 75, when most people may have lost sufficient trabecular bone for the hip to fracture with the impact of a fall.

#### BONE MINERAL DENSITY AND VERTEBRAL BODY FRACTURES

As for the hip, loss of bone mineral density in the vertebral bodies predisposes to fracture. Particularly low bone density is associated with more extensive fractures,<sup>48</sup> which are more likely to be symptomatic. The difference between cases and controls in bone density for asymptomatic vertebral body crush fractures detected in radiographic surveys was only about half a standard deviation—similar to that for the neck of femur<sup>14 24 39 48-50</sup>—but for hospital outpatients with symptomatic fractures the difference was greater—generally between 1 and 1½ standard deviations.<sup>14 17 22 25-27 35 51-53</sup> There could have been bone loss after the fracture but before the measurement because of immobility in the symptomatic cases, but even with this greater discrimination for the symptomatic cases the effectiveness of screening would be only moderate, with a detection rate of about 25% for a 2% false positive rate, or 35% for a 5% false positive rate. Our knowledge of the incidence and natural course of symptomatic fractures and the effectiveness of preventive measures is limited, and with this uncertainty screening for vertebral body fractures cannot at present be recommended.

#### OVERALL INTERPRETATION

Measurement of bone mineral density is not a useful screening test for future hip fracture or for most vertebral fractures because differences in bone density between people who subsequently have a fracture and those who do not are too small to discriminate between them. This does not mean that strategies to increase the average bone mineral density of an entire population will fail to reduce the incidence of hip fracture. On the contrary, as discussed in the next section, such strategies are likely to succeed.

## 2 Directing preventive measures to all women

### HORMONE REPLACEMENT THERAPY

Randomised trials of up to 10 years' duration have shown that oestrogen replacement substantially or totally prevents postmenopausal bone loss.<sup>54-58</sup> Observational studies (up to the age of 80<sup>12</sup>) have shown the same effect; bone loss is prevented for as long as treatment is maintained. Observational studies have also, with one exception, shown that oestrogen protects against hip fracture (table V), with a median reduction in incidence of 50% in women who had at some time received postmenopausal oestrogen therapy. Combined preparations of oestrogen and progestogen have not been used for long enough to provide information on their effect on risk of hip fracture, but a preventive effect is likely because they prevent rapid postmenopausal bone loss in the same way as oestrogen alone.<sup>55-57</sup>

The main limitation of the case-control studies of hormone replacement therapy and hip fracture is that they were generally based on comparatively young women (mostly under 75) who if they took oestrogen, did so for decades. The relative risk estimates therefore tend to reflect current and prolonged use in younger women. Data from four studies (table VI) show that, while current use reduces risk of hip fracture by more than half, this protection is substantially lost within a



TABLE VI—Age adjusted risk of hip fracture according to time since last taking postmenopausal oestrogen

Study centre	Time since last taking oestrogen (years)	Relative risk	
<i>Case-control studies</i>			
Seattle <sup>62*</sup>	Current	0.4	
	1-2	0.7	
	3-5	1.0	
	≥6	0.8	
Los Angeles <sup>61</sup>	Never	1.0	
	Current	0.4†	
	1-2	0.7	
	3-5	0.8	
	6-9	1.5	
Los Angeles <sup>63</sup>	≥10	0.8	
	Never	1.0	
	<i>Prospective studies</i>		
	0-1	0.8	
	2-14	0.9	
Framingham <sup>64</sup>	≥15	1.2	
	Never	1.0	
	0-2	0.3	
	>2	0.7	
	Never	1.0	

\*Risk of hip or forearm fracture. †Data provided by author.

few years after stopping hormone replacement therapy. This is consistent with the results of two randomised trials of oestrogen replacement and bone density, which showed that a period of rapid bone loss occurred after stopping oestrogen replacement, similar in magnitude to the rapid postmenopausal bone loss in the controls, who did not take oestrogen.<sup>57,58</sup> Eight years after oophorectomy bone mineral density was only slightly greater in women who took oestrogen for the first four years than in women who had never taken oestrogen.<sup>58</sup>

With protection lost so soon after stopping hormone replacement, taking oestrogen for only a few years after the menopause can have little effect on reducing the risk of hip fracture. Even if oestrogen was taken to the age of 70 there would be little protective effect in women over the age of 75, in whom over 80% of hip fractures occur (including almost all those complicated by loss of mobility and need for institutional care). Hormone replacement therapy is likely to have an appreciable impact on the public health problem of hip fracture only if it is continued indefinitely after the menopause. Such a policy would be a radical departure from current practice in Britain, and assessment of the advantages and disadvantages would be complex. For oestrogen alone the protection against ischaemic heart disease seems substantial while the increase in breast cancer is small.<sup>68</sup> However, if combined (oestrogen plus progestogen) preparations are to be preferred because of their lower risk of endometrial cancer the indefinite prolongation of menstrual bleeding with current preparations could be unacceptable to women, and the effect of progestogen on the risk of cardiovascular diseases has not been established.

Oral contraceptives in current use seem to have little effect on bone density, but previously used preparations with higher oestrogen content may have increased bone density.<sup>8,9,69-71</sup>

#### STOPPING SMOKING

Cross sectional studies have shown that among premenopausal women bone density is similar in smokers and non-smokers, but that some years after the menopause a lower bone density becomes apparent in smokers.<sup>70-73</sup> Smoking accelerates the rate of postmenopausal bone loss.<sup>73</sup> Table VII lists risk estimates from 10 observational studies of smoking and hip fracture: Four of the studies recruited only women<sup>59,61,74,78</sup>; the others recruited men and women, and there was no significant sex difference in the effect of smoking on the risk of hip fracture. The risk increases with the amount smoked, but the median relative risk estimate is 1.4. This suggests that a woman

who stops smoking before the menopause would, on average, reduce her risk of eventual hip fracture by about a quarter (from 1.4 to 1.0), and that in a community where one third of postmenopausal women smoke about an eighth of all hip fractures are attributable to smoking. For heavier smokers stopping smoking could halve the risk.

As the prevalence of smoking among older women has increased over the past few decades smoking is likely to have been a contributing factor, albeit a minor one, in the doubling of the incidence of hip fracture, at least in women. For vertebral body fractures there is a higher relative risk—about threefold—in smokers.<sup>76</sup>

The lower bone density of older smokers is partly due to their lower body weight,<sup>72</sup> thin people having less dense bones on average. The relative risk estimate for smokers in the Connecticut study, unadjusted for body weight, was 1.5 (table VII), but this reduced to 1.3 if the lower body weight of smokers was allowed for.<sup>74</sup> In the Seattle study the unadjusted relative risk estimate was 1.4 and the adjusted estimate 1.2.<sup>59</sup> People who give up smoking should ideally, on general health grounds, maintain their lower body weight, albeit at the expense of an increased risk of hip fracture. The greater part of the effect of smoking on bone density and the risk of hip fracture is, however, independent of body weight and likely to be mediated through other mechanisms.<sup>72</sup> The suggestion that smoking merely counteracts the protective effect of postmenopausal exogenous oestrogen replacement<sup>78</sup> is inconsistent with the effect of smoking on incidence of hip fracture in the Southampton study (table VII), in which only 3% of the subjects had ever taken postmenopausal oestrogen.

#### EXERCISE

Exercise increases peak bone mineral density in youth. Cross sectional studies have shown greater bone mineral density and greater cortical bone mass in sportsmen and sportswomen, athletes, and dancers than in age matched controls.<sup>80-83</sup> Measurements before and after intense physical training have shown increases in bone mineral content and cortical area.<sup>84,85</sup> In six clinical trials in postmenopausal women (mean age between 51 and 63), exercise programmes increased bone density, reversing the normal postmenopausal loss of bone seen in the randomised or matched control women who did not exercise.<sup>86-91</sup> Two trials in elderly people (over 70) showed the same effect.<sup>92,93</sup> Cross sectional studies have shown that women who exercised at least three times a week had

TABLE VII—Results of studies of effect of cigarette smoking on risk of hip fracture

Study centre	Smoking category	Relative risk v never smokers (95% confidence interval)*
<i>Case-control studies</i>		
Los Angeles <sup>61</sup>	1-10 Cigarettes/day after menopause	1.1†
	≥11 Cigarettes/day after menopause	2.0
Connecticut <sup>74</sup>	Ever smokers	1.5†
Seattle <sup>59</sup>	Ever smokers	1.4 (1.0 to 2.0)‡
Hong Kong <sup>75</sup>	Ever smokers	1.3 (1.0 to 1.7)†
Oxford <sup>6</sup>	Ever smokers	1.2
Southampton <sup>65</sup>	1-9 Pack years	1.2 (0.8 to 1.9)‡§
	10-19 Pack years	2.8 (1.8 to 4.6)
	≥20 Pack years	1.6 (1.0 to 2.6)
<i>Prospective studies</i>		
Los Angeles <sup>63</sup>	1-10 Cigarettes/day	1.3 (0.7 to 2.2)‡§
	≥11 Cigarettes/day	2.1 (1.5 to 3.0)
Britain (DHSS survey) <sup>77</sup>	Smoker at time of interview	5.6 (1.8 to 17.7)
Framingham <sup>78</sup>	Smoker at time of interview	1.2 (0.8 to 1.6)‡
San Diego <sup>79</sup>	Smoker at time of interview	1.1‡

\*Not available for all studies.

†Adjusted for the effect of other risk factors but not body mass index.

‡Adjusted for the effect of other risk factors including body mass index.

§Data supplied by author.

||Calculated by us from published data.

TABLE VIII—Results of studies of effect of regular exercise on risk of hip fracture

Study centre	Extent of habitual exercise	Relative risk (95% confidence interval)
<i>Case-control studies</i>		
Los Angeles <sup>61</sup>	Frequency of active outdoor games:	
	Low	1.0
	Medium	0.5*
Hong Kong <sup>76</sup>	Habitual walking uphill:	
	<Once/day	1.0
Southampton <sup>69</sup>	Physical activity:	
	≤2 Hours/week	1.0
	3-4 Hours/week	0.6 (0.4 to 0.9)*†
	≥5 Hours/week	0.4 (0.3 to 0.7)
	Previous occupation:	
Oxford <sup>100</sup>	Sedentary	1.0
	Intermediate	0.3 (0.2 to 0.6)*†
	Weight bearing	0.3 (0.2 to 0.5)
Los Angeles <sup>65</sup>	Past activity:	
	Very inactive	1.0
	Moderately inactive	0.7 (0.4 to 1.2)‡
Britain (DHSS) <sup>77</sup>	Active	0.5 (0.3 to 0.8)
	<i>Prospective studies</i>	
	Active exercise:	
	<1/2 Hour/day	1.0
1/2-1 Hour/day	0.7 (0.6 to 0.9)*	
≥1 Hour/day	0.6 (0.5 to 0.7)	
Los Angeles <sup>65</sup>	Outdoor activity:	
	Low	1.0
	Moderate	1.1 (0.3 to 4.3)*†
	High	0.3 (0.04 to 1.4)

\*Adjusted for the effect of other risk factors.

†Data supplied by author.

‡Calculated by us from published data.

higher bone density than sedentary women at all ages from 20 to 80<sup>13</sup>; that habitual exercise, physical fitness, and muscle strength were all correlated with bone density in premenopausal and postmenopausal women and in men aged from 31 to 75<sup>94,97</sup>; and that physical fitness and muscle strength were independent determinants of femoral neck bone density.<sup>96</sup> In elderly people exercise is also likely to reduce the risk of falling.<sup>98</sup>

Table VIII lists estimates of the relative risk of hip fracture according to habitual exercise from six observational studies. The effect of regular exercise was substantial, reducing the risk of hip fracture by about half. Five of the studies recruited men and women, and recorded similar estimates for both sexes. The protection is likely to be permanent as the effect of occupation was apparent years after retirement.<sup>99</sup> The effect of exercise on bone density is not localised to the exercised limb,<sup>81,87</sup> and many different types of activity have been shown to increase bone density or reduce risk of hip fracture, although weight bearing exercise is probably preferable.<sup>101</sup> Brisk walking alone did not seem to prevent bone loss,<sup>87,102</sup> although an observational study suggested a modest protective effect against hip fracture.<sup>63</sup>

Reduction in habitual physical activity is likely to be the major reason for the doubling of rates of hip fracture over the past 30 years or so. With increased mechanisation our lives have become less physically demanding. This is shown by the decline in average calorie intake in Britain—from 11.9 MJ (2840 kcal) per person per day in 1965 to 9.8 MJ (2350 kcal) in 1985.<sup>103</sup> Other factors cannot readily account for this decline—there is no indication that people have become thinner, and the effect of the slightly higher mean age of the population in 1985 is trivial—and the 2.1 MJ (490 kcal) fall in energy expenditure over the 20 years reflects a substantial reduction in physical activity. A simple calculation allowing 6.3 MJ (1500 kcal) to sustain resting metabolic rate suggests a fall of about a third in energy expenditure for physical activity (from 5.6 MJ to 3.5 MJ (1340 kcal to 850 kcal) per day).

As exercise is a major protective factor against hip fracture, conversely, immobilisation is an important

cause. Immobilisation leads directly to a reduction in bone density, particularly in weight bearing bones such as the femur, and the decline in muscle mass consequent on immobilisation further reduces bone density.<sup>101</sup> A history of immobilisation for more than three weeks in the previous 10 years was associated with a twofold increased incidence of hip fracture in one study,<sup>61</sup> and permanently impaired mobility was associated with a fourfold to fivefold increased incidence.<sup>77,100</sup> The potential for recovery is lost after a few months, and prolonged immobilisation produces irreversible loss of bone.<sup>101</sup> Immobilisation should be avoided if at all possible; exercises may be useful if it is unavoidable.

#### ALCOHOL

Alcoholics have low bone density<sup>104,105</sup> and a considerably increased risk of hip fracture—fourfold and eightfold increases in two case-control studies.<sup>63,64</sup> Cross sectional studies of healthy postmenopausal women, however, have shown no deleterious effect of moderate alcohol consumption on bone density.<sup>8,9,70,106</sup> There is an increased risk of hip fracture of about 30% associated with moderate alcohol consumption<sup>61,63,65,79,107</sup> but this need not imply an effect on bone density; alcohol taken before the fracture could have predisposed to the fall.

#### CALCIUM SUPPLEMENTATION

The value of calcium supplementation of the diet has recently been discussed at length, but with no consensus.<sup>108-110</sup> Interpretation of the evidence is complex. Peak bone density seems to be associated with dietary calcium intake in childhood.<sup>110,111</sup> Thereafter, in both premenopausal and postmenopausal women some observational studies have shown an association of dietary calcium with bone density or rates of bone loss,<sup>111</sup> while others failed to do so.<sup>70,71,106,111</sup> However, six randomised trials of the effect of pharmaceutical preparations of calcium on bone density in postmenopausal or elderly women have all shown a reduction in the rate of bone loss in the femur<sup>112,113</sup> or forearm<sup>54,93,113-115</sup> (although the reduction was less certain in the spine<sup>112,113</sup>). The effect in the trials was definite but modest—less than half that produced by oestrogen replacement<sup>54,115</sup> and less pronounced in women with higher dietary calcium content.<sup>113</sup> The failure of some of the observational studies to show the weak association may be attributable to the imprecision inherent in estimating calcium intake from food frequency questionnaires<sup>110</sup> and to the variable absorption of dietary calcium.<sup>115</sup> The randomised trials must be given greater evidential weight, and on the basis of these there is evidence that calcium supplementation has a small beneficial effect on bone density.

Observational studies on dietary calcium and hip fracture are also inconclusive, perhaps for the same reasons. A study from Hong Kong showed a significant inverse association, but the average calcium intake was only about a quarter of that typical of Western countries.<sup>75</sup> Of five American and British studies, only one showed a significant association<sup>79</sup> and four suggested very little or no association.<sup>28,63,65,77</sup> Despite these inconclusive results calcium supplementation must offer some protection against hip fracture because it reduces postmenopausal bone loss; but the degree of protection is likely to be small as the effect on bone density is only modest and a large protective effect against hip fracture would have been detected by the observational studies taken collectively. Also, as with oestrogen replacement, the protection against hip fracture would probably be lost rapidly after calcium supplementation had stopped, so that to maintain prophylaxis supplementation would have to be continued indefinitely.

Costs are an important consideration. The trials of calcium supplementation and bone density used an average dose of over 1g a day, much more than could be provided by simple dietary supplementation. Pharmaceutical preparations of calcium are expensive (because simple preparations are poorly absorbed and chewable or effervescent preparations are needed<sup>16</sup>); they cost more than the cheaper forms of hormone replacement. To treat all women aged over 50 in Britain the annual cost would be over £500 million—about 15% of the total NHS drug expenditure. Unlike the other interventions, calcium supplementation lacks other proved health benefits (though it may lower blood pressure). The likely effect on risk of hip fracture is too small to justify recommending that postmenopausal and elderly women should take calcium supplementation.

## Conclusions

Hip fracture is an important cause of morbidity and contributes considerably to the cost of health care in the Western World. Several strategies could help reduce the loss of bone density that underlies hip fracture. Among these, a substantial body of evidence indicates that physical activity is the most important, and it is a method of prevention that can be enjoyable and sociable. Regular exercise would reduce the risk of hip fracture by at least half, thereby preventing some 20 000 cases of hip fracture each year in Britain. Stopping smoking is also important, and a woman who stops smoking before the menopause will reduce her risk by about a quarter. Both these policies can be adopted by both sexes and continued into old age. Postmenopausal oestrogen replacement more than halves the risk of hip fracture, but the loss of this protection within a few years of stopping treatment limits its utility. Oestrogen replacement would need to be continued almost indefinitely if it were to do more than reduce the incidence of hip fracture in younger age groups, in whom hip fracture is uncommon and recovery generally uncomplicated. General calcium supplementation is not justified as the likely benefit is too small.

These preventive measures need to be directed towards the entire population. Their selective use, together with drugs, in a minority of the population identified by measurement of bone mineral density as a screening test is likely to have little impact on the incidence of hip fracture—the detection rate of such a test is too low and the false positive rate too high. Even if a more effective screening test were available, the preventive measures have the additional advantage of being of general health benefit, protecting against ischaemic heart disease in particular, and there is no good reason to confine them to women judged as being at high risk of hip fracture.

We thank the following investigators who gave us unpublished data for referenced studies: Professor A Paganini-Hill,<sup>61,65</sup> Dr C Cooper,<sup>63</sup> and Dr C Wickham.<sup>63,77,99</sup> We also thank Dr C Cooper, Dr T Spector, and Professor J Garrow for their comments on the manuscript and Christopher Frost for statistical advice.

- Office of Population Censuses and Surveys. *Hospital Inpatient Enquiry*, 1985. London: HMSO, 1987.
- Boyce WJ, Vessey MP. Rising incidence of fracture of the proximal femur. *Lancet* 1985;i:150-1.
- Spector TD, Cooper C, Fenton Lewis A. Trends in admissions for hip fracture in England and Wales, 1968-85. *BMJ* 1990;300:173-4.
- Sartoris DJ, Sommer FG, Kosek J, Gies A, Carter D. Dual-energy projection radiography in the evaluation of femoral neck strength, density, and mineralization. *Invest Radiol* 1985;20:476-85.
- Leichter I, Margulies JY, Weinreb A, Mizrahi J, Robin GC, Conforty B, et al. The relationship between bone density, mineral content, and mechanical strength in the femoral neck. *Clin Orthop* 1982;163:272-81.
- Dalen N, Hellström L-G, Jacobson B. Bone mineral content and mechanical strength of the femoral neck. *Acta Orthop Scand* 1976;47:503-8.
- Mazess RB. On aging bone loss. *Clin Orthop* 1982;165:239-52.
- Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of

- bone density in normal women: risk factors for future osteoporosis? *BMJ* 1989;298:924-8.
- Hall ML, Heavens J, Cullum ID, Ell PJ. The range of bone density in normal British women. *Br J Radiol* 1990;63:266-9.
- Mazess RB, Barden HS, Ettinger M, Johnston C, Dawson-Hughes B, Baron D, et al. Spine and femur density using dual-photon absorptiometry in US white women. *Bone Miner* 1987;2:211-9.
- van Hemert AM, Vandenbroucke JP, Hofman A, Valkenburg HA. Metacarpal bone loss in middle-aged women: "horse-racing" in a 9-year population based follow-up study. *J Clin Epidemiol* 1990;43:579-88.
- Quigley MET, Martin PL, Burnier AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. *Am J Obstet Gynecol* 1987;156:1516-23.
- Talmage RV, Stinnett SS, Landwehr JT, Vincent LM, McCartney WH. Age-related loss of bone mineral density in non-athletic and athletic women. *Bone Miner* 1986;1:115-25.
- Riggs BL, Wahner HW, Melton LJ, Richelson LS, Judd HL, Offord KP. Rates of bone loss in the appendicular and axial skeletons of women. *J Clin Invest* 1986;77:1487-91.
- Riggs BL, Melton LJ. Involutional osteoporosis. *N Engl J Med* 1986;314:1676-86.
- Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, et al. Changes in bone mineral density of the proximal femur and spine with aging. *J Clin Invest* 1982;70:716-23.
- Norimatsu H, Mori S, Uesato T, Yoshikawa T, Katsuyama N. Bone mineral density of the spine and proximal femur in normal and osteoporotic subjects in Japan. *Bone Miner* 1989;5:213-22.
- Bohr H, Schaadt O. Bone mineral content of femoral bone and the lumbar spine measured in women with fracture of the femoral neck by dual photon absorptiometry. *Clin Orthop* 1983;179:240-5.
- Eriksson SAV, Widhe TL. Bone mass in women with hip fracture. *Acta Orthop Scand* 1988;59:19-23.
- Melton LJ, Eddy DM, Johnston CC. Screening for osteoporosis. *Ann Intern Med* 1990;112:516-28.
- Chevalley T, Rizzoli R, Nydegger V, Slosman D, Tkatch L, Rapin C, et al. Preferential low bone mineral density of the femoral neck in patients with a recent fracture of the proximal femur. *Osteoporosis International* 1991;1:147-54.
- Krolner B, Pors Nielsen S. Bone mineral content of the lumbar spine in normal and osteoporotic women: cross-sectional and longitudinal studies. *Clin Sci* 1982;62:329-36.
- Cornell CN, Schwartz S, Bansal M, Lane JM, Bullough P. Quantification of osteopenia in hip fracture patients. *J Orthop Trauma* 1988;2:212-7.
- Meltzer M, Lessig HJ, Siegel JA. Bone mineral density and fracture in postmenopausal women. *Calcif Tissue Int* 1989;45:142-5.
- Mazess RB, Barden H, Ettinger M, Schultz E. Bone density of the radius, spine, and proximal femur in osteoporosis. *J Bone Miner Res* 1988;3:13-8.
- Härmä M, Karjalainen P, Hoikka V, Alhava E. Bone density in women with spinal and hip fractures. *Acta Orthop Scand* 1985;56:380-5.
- Fircoznia H, Raffi M, Golimbu C, Schwartz MS, Orr P. Trabecular mineral content of the spine in women with hip fracture. CT measurement. *Radiology* 1986;159:737-40.
- Wootton R, Brereton PJ, Clark MB, Hesp R, Hodkinson HM, Klenerman L, et al. Fractured neck of femur in the elderly: an attempt to identify patients at risk. *Clin Sci* 1979;57:93-101.
- Jensen GF, Christiansen C, Boesen J, Hegedüs V, Transbøl I. Epidemiology of postmenopausal spinal and long bone fractures. *Clin Orthop* 1982;166:75-81.
- Elsasser U, Hesp R, Klenerman L, Wootton R. Deficit of trabecular and cortical bone in elderly women with fracture of the femoral neck. *Clin Sci* 1980;59:393-5.
- Lips P, Taconis WK, van Ginkel FC, Netelenbos JC. Radiologic morphometry in patients with femoral neck fractures and elderly control subjects. *Clin Orthop* 1984;183:64-70.
- Aitken JM. Relevance of osteoporosis in women with fracture of the femoral neck. *BMJ* 1984;288:597-601.
- Cook PJ, Exton-Smith AN, Brocklehurst JC, Lempert-Barber SM. Fractured femurs, falls and bone disorders. *J R Coll Physicians Lond* 1982;16:45-9.
- Horsman A, Nordin C, Simpson M, Speed R. Cortical and trabecular bone status in elderly women with femoral neck fracture. *Clin Orthop* 1982;166:143-51.
- Hassager C, Christiansen C. Influence of soft tissue body composition on bone mass and metabolism. *Bone* 1989;10:415-9.
- Vega E, Mautalen C, Gómez H, Garrido A, Melo L, Sahores AO. Bone mineral density in patients with cervical and trochanteric fractures of the proximal femur. *Osteoporosis International* 1991;1:81-6.
- Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK. Appendicular bone density and age predict hip fracture in women. *JAMA* 1990;263:665-8.
- Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. *J Clin Invest* 1988;81:1804-9.
- Wasnich RD, Ross PD, Heilbrun LK, Vogel JM. Prediction of postmenopausal fracture risk with use of bone mineral measurements. *Am J Obstet Gynecol* 1985;153:745-51.
- Porter RW, Miller CG, Grainger D, Palmer SB. Prediction of hip fracture in elderly women: a prospective study. *BMJ* 1990;301:638-41.
- van Hemert AM, Vandenbroucke JP, Birkenhager JC, Valkenburg HA. Prediction of osteoporotic fractures in the general population by a fracture risk score. *Am J Epidemiol* 1990;132:123-35.
- Nordin BEC, Need AG, Chatterton BE, Horowitz M, Cleghorn DB. Bone density screening for osteoporosis. *Lancet* 1990;336:1327-8.
- Cooper C, Barker DJP, Morris J, Briggs RSJ. Osteoporosis, falls and age in fracture of the proximal femur. *BMJ* 1987;295:13-5.
- Pogrand H, Rigal WM, Makin M, Robin G, Mencil J, Steinberg R. Determination of osteoporosis in patients with fractured femoral neck using the Singh index: a Jerusalem study. *Clin Orthop* 1981;156:189-95.
- Dequeker J, Gautama K, Roh YS. Femoral trabecular patterns in asymptomatic spinal osteoporosis and femoral neck fracture. *Clin Radiol* 1974;25:243-6.
- Lotz JC, Gerhart TN, Hayes WC. Mechanical properties of trabecular bone from the proximal femur: a quantitative CT study. *J Comput Assist Tomogr* 1990;14:107-14.
- Khairi MRA, Cronin JH, Robb JA, Smith DM, Yu PL, Johnston CC. Femoral trabecular-pattern index and bone mineral content measurement by photon absorption in senile osteoporosis. *J Bone Joint Surg [Am]* 1976;58:221-6.
- Pacifici R, Susman N, Carr PL, Birge SJ, Avioli LV. Single and dual energy



- tomographic analysis of spinal trabecular bone: a comparative study in normal and osteoporotic women. *J Clin Endocrinol Metab* 1987;64:209-14.
- 49 Melton LJ, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. *Am J Epidemiol* 1989;129:1000-11.
  - 50 Lee ST, Yeang M, Balasubramanian P, Bose K. Bone mineral content of a normal Asian population in Singapore—a cross-sectional study. In: Christiansen C, Johansen JS, Riis BJ, eds. *Osteoporosis 1987*. Copenhagen: Osteopress, 1987:180-5.
  - 51 Robinson B, Wagstaffe C, Roche J, Clifton-Bligh P, Posen S. Is there a place for forearm osteodensitometry in clinical screening studies? *Med J Aust* 1987;146:297-9.
  - 52 Cohn SH, Aloia JF, Vaswani AN, Yuen K, Yasumura S, Ellis KJ. Women at risk for developing osteoporosis: determination by total body neutron activation analysis and photon absorptiometry. *Calcif Tissue Int* 1986;38:9-15.
  - 53 Nordin BEC, Robertson A, Seamark RF, Bridges A, Philcox JC, Need AG, et al. The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. *J Clin Endocrinol Metab* 1985;60:651-7.
  - 54 Recker RR, Saville PD, Heaney RP. Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. *Ann Intern Med* 1977;87:649-55.
  - 55 Munk-Jensen N, Nielsen SP, Obel EB, Eriksen PB. Reversal of postmenopausal vertebral bone loss by oestrogen and progesterone: a double blind placebo controlled study. *BMJ* 1988;296:1150-2.
  - 56 Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. *Obstet Gynecol* 1979;53:277-81.
  - 57 Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. *Lancet* 1981;ii:459-61.
  - 58 Lindsay R, Hart DM, MacLean A, Clark AC, Kraszewski A, Garwood J. Bone response to termination of oestrogen treatment. *Lancet* 1978;ii:1325-7.
  - 59 Williams AR, Weiss NS, Ure CL, Ballard J, Daling JR. Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. *Obstet Gynecol* 1982;60:695-9.
  - 60 Johnson RE, Specht EE. The risk of hip fracture in postmenopausal females with and without estrogen drug exposure. *Am J Public Health* 1981;71:138-44.
  - 61 Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. *Ann Intern Med* 1981;95:28-31.
  - 62 Kreiger N, Kelsey JL, Holford TR, O'Connor T. An epidemiologic study of hip fracture in postmenopausal women. *Am J Epidemiol* 1982;116:141-8.
  - 63 Cooper C, Barker DJP, Wickham C. Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain. *BMJ* 1988;297:1443-7.
  - 64 Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal radius. *Lancet* 1979;ii:705-9.
  - 65 Paganini-Hill A, Chao A, Ross RK, Henderson BE. Exercise and other factors in the prevention of hip fracture: the Leisure World study. *Epidemiology* 1991;ii:16-25.
  - 66 Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. *N Engl J Med* 1987;317:1169-74.
  - 67 Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. *N Engl J Med* 1980;303:1195-8.
  - 68 Hunt K, Vessey M. Long-term effects of postmenopausal hormone therapy. *Br J Hosp Med* 1987;38:450-3, 456-60.
  - 69 Goldsmith NF, Johnston JO. Bone mineral: effects of oral contraceptives, pregnancy, and lactation. *J Bone Joint Surg [Am]* 1975;57:657-68.
  - 70 Hansen MA, Overgaard K, Riis BJ, Christiansen C. Potential risk factors for development of postmenopausal osteoporosis—examined over a 12-year period. *Osteoporosis International* 1991;1:95-102.
  - 71 Mazess R, Barden HS. Bone density in premenopausal women: effects of age, dietary intake, physical activity, smoking, and birth-control pills. *Am J Clin Nutr* 1991;53:132-42.
  - 72 Law M. Smoking and osteoporosis. In: Wald NJ, Baron J, eds. *Smoking and hormone-related disorders*. Oxford: Oxford University Press, 1990:83-92.
  - 73 Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. *J Bone Miner Res* 1991;6:331-7.
  - 74 Kreiger N, Hilditch S. Cigarette smoking and estrogen-dependent diseases. *Am J Epidemiol* 1986;123:200.
  - 75 Lau E, Donnan S, Barker DJP, Cooper C. Physical activity and calcium intake in fracture of the proximal femur in Hong Kong. *BMJ* 1988;297:441-3.
  - 76 Cooper C, Wickham C. Cigarette smoking and the risk of age-related fractures. In: Wald NJ, Baron J, eds. *Smoking and hormone-related disorders*. Oxford: Oxford University Press, 1990:93-100.
  - 77 Wickham CA, Walsh K, Cooper C, Barker DTP, Margetts BM, Morris J, et al. Dietary calcium, physical activity, and risk of hip fracture: a prospective study. *BMJ* 1989;299:889-92.
  - 78 Kiel DP, Baron JA, Anderson JJ, Felson DT. Cigarette smoking counteracts the effects of oral estrogens on hip fracture. *Clin Res* 1990;38:512A.
  - 79 Holbrook TL, Barrett-Connor E, Wingard DL. Dietary calcium and risk of hip fracture: 14-year prospective population study. *Lancet* 1988;ii:1046-9.
  - 80 Jones HH, Priest JD, Hayes WC, Tichenor CC, Nagel DA. Humeral hypertrophy in response to exercise. *J Bone Joint Surg [Am]* 1977;59:204-8.
  - 81 Dalen N, Olsson KE. Bone mineral content and physical activity. *Acta Orthop Scand* 1974;45:170-4.
  - 82 Nilsson BE, Westlin NE. Bone density in athletes. *Clin Orthop* 1971;77:179-82.
  - 83 Nilsson BE, Andersson SM, Havdrup T, Westlin NE. Ballet-dancing and weight-lifting—effects on BMC. *AJR* 1978;131:541-2.
  - 84 Margulies JY, Simkin A, Leichter I, Bivas A, Steinberg R, Giladi M, et al. Effect of intense physical activity on the bone-mineral content in the lower limbs of young adults. *J Bone Joint Surg [Am]* 1986;68:1090-3.
  - 85 Woo SLY, Kuei SC, Amiel D, Gomez MA, Hayes WC, White FC, et al. The effect of prolonged physical training on the properties of long bones: a study of Wolff's law. *J Bone Joint Surg [Am]* 1981;63:780-7.
  - 86 Chow A, Harrison JE, Notarius C. Effect of two randomised exercise programmes on mass of healthy postmenopausal women. *BMJ* 1987;295:1441-4.
  - 87 White MK, Martin RB, Yeater RA, Butcher RL, Radin EL. The effects of exercise on the bones of postmenopausal women. *Int Orthop* 1984;7:209-14.
  - 88 Aloia JF, Cohn SH, Ostuni JA, Cane R, Ellis K. Prevention of involutional bone loss by exercise. *Ann Intern Med* 1978;89:356-8.
  - 89 Smith EL, Smith PE, Ensign CJ, Shea MM. Bone involution decrease in exercising middle-aged women. *Calcif Tissue Int* 1984;36:S129-38.
  - 90 Kroiner B, Toft B, Pors Nielsen S, Tondevdov E. Physical exercise as prophylaxis against involutional vertebral bone loss: a controlled trial. *Clin Sci* 1983;64:541-6.
  - 91 Simkin A, Ayalon J, Leichter I. Increased trabecular bone density due to bone-loading exercises in postmenopausal osteoporotic women. *Calcif Tissue Int* 1987;40:59-63.
  - 92 Rundgren A, Aniansson A, Ljungberg P, Wetterqvist K. Effects of a training programme for elderly people on mineral content of the heel bone. *Archives of Gerontology and Geriatrics* 1984;3:243-8.
  - 93 Smith E, Reddan W, Smith P. Physical activity and calcium modalities for bone mineral increase in aged women. *Med Sci Sports Exerc* 1981;13:60-4.
  - 94 Sinaki M, Offord KP. Physical activity in postmenopausal women: effect on back muscle strength and bone mineral density of the spine. *Arch Phys Med Rehabil* 1988;69:277-80.
  - 95 Pocock NA, Eisman JA, Yeates MG, Sambrook PN, Eberl S. Physical fitness is a major determinant of femoral neck and lumbar spine bone mineral density. *J Clin Invest* 1986;78:618-21.
  - 96 Pocock N, Eisman J, Gwinn T, Sambrook P, Kelly P, Freund J, et al. Muscle strength, physical fitness and weight but not age predict femoral neck bone mass. *J Bone Miner Res* 1989;4:441-8.
  - 97 Suominen H, Heikkinen E, Vainio P, Lahtinen T. Mineral density of calcaneus in men at different ages: a population study with special reference to life-style factors. *Age Ageing* 1984;13:273-81.
  - 98 Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians: effects on skeletal muscle. *JAMA* 1990;263:3029-34.
  - 99 Cooper C, Wickham C, Coggon D. Sedentary work in middle life and fracture of the proximal femur. *Br J Ind Med* 1990;47:69-70.
  - 100 Boyce WJ, Vessey MP. Habitual physical inertia and other factors in relation to risk of fracture of the proximal femur. *Age Ageing*, 1988;17:319-27.
  - 101 Minaire P. Immobilisation osteoporosis: a review. *Clin Rheumatol* 1989;8 (suppl 2):95-103.
  - 102 Cavanaugh DJ, Cann CE. Brisk walking does not stop bone loss in postmenopausal women. *Bone* 1988;9:201-4.
  - 103 Ministry of Agriculture, Fisheries and Food. *Annual report of the National Food Survey Committee. Household food consumption and expenditure, 1985*. London: HMSO, 1987.
  - 104 Rico H. Alcohol and bone disease. *Alcohol* 1990;25:345-52.
  - 105 Lalor BC, France MW, Powell D, Adams PH, Counihan TB. Bone and mineral metabolism and chronic alcohol abuse. *Q J Med* 1986;59:497-511.
  - 106 Angus RM, Sambrook PN, Pocock NA, Eisman JA. Dietary intake and bone mineral density. *Bone Miner* 1988;4:265-77.
  - 107 Felson DT, Kiel DP, Anderson JJ, Kannel WB. Alcohol consumption and hip fractures: the Framingham study. *Am J Epidemiol* 1988;128:1102-10.
  - 108 Kanis JA, Passmore R. Calcium supplementation of the diet: not justified by present evidence. *BMJ* 1989;298:137-40, 205-8.
  - 109 Nordin BEC, Heaney RP. Calcium supplementation of the diet: justified by present evidence. *BMJ* 1990;300:1056-60.
  - 110 Angus RM, Eisman JA. Osteoporosis: the role of calcium intake and supplementation. *Med J Aust* 1988;148:630-3.
  - 111 Cumming RG. Calcium intake and bone mass: a quantitative review of the evidence. *Calcif Tissue Int* 1990;47:194-201.
  - 112 Lamke B, Sjöberg H-E, Sylven M. Bone mineral content in women with Colles' fracture: effect of calcium supplementation. *Acta Orthop Scand* 1978;49:143-6.
  - 113 Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med* 1990;323:878-83.
  - 114 Smith EL, Gilligan C, Smith PE, Sempos CT. Calcium supplementation and bone loss in middle-aged women. *Am J Clin Nutr* 1989;50:833-42.
  - 115 Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? *N Engl J Med* 1987;316:173-7.
  - 116 Heaney RP. Calcium supplements: practical considerations. *Osteoporosis International* 1991;1:65-71.

(Accepted 6 March 1991)